AMPK: A promising molecular target for combating cisplatin toxicities

Biochem Pharmacol. 2019 May:163:94-100. doi: 10.1016/j.bcp.2019.02.006. Epub 2019 Feb 7.

Abstract

Cisplatin is a broadly prescribed anti-tumor agent for the treatment of diverse cancers. Therapy with cisplatin, however, is associated with various adverse effects including nephrotoxicity and ototoxicity. AMP kinase (AMPK), an evolutionarily conserved enzyme, functions as the fundamental regulator of energy homeostasis. While AMPK activation protects normal tissues against cisplatin-induced toxicities, its impact in cancer is context-dependent and there is no single, uniform role for AMPK. On one hand, some report that AMPK activation augments cisplatin-induced apoptosis in cancer, while on the other hand, few reports indicate that AMPK activation rescues cancer cells from the cytotoxicity induced by cisplatin. Here we review the most salient signaling pathways regulated by AMPK with an emphasis on their relation to cisplatin toxicity and yet discuss context-dependent functions of AMPK in cancer.

Keywords: AMP-activated kinase; Cisplatin; Toxicity.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • AMP-Activated Protein Kinase Kinases
  • Animals
  • Antineoplastic Agents / toxicity*
  • Cell Line, Tumor
  • Cisplatin / toxicity*
  • Drug Delivery Systems / methods*
  • Drug Delivery Systems / trends
  • Enzyme Activation / drug effects
  • Enzyme Activation / physiology
  • Humans
  • Neoplasms / drug therapy
  • Neoplasms / enzymology*
  • Protein Kinases / metabolism*
  • Signal Transduction / drug effects
  • Signal Transduction / physiology

Substances

  • Antineoplastic Agents
  • Protein Kinases
  • AMP-Activated Protein Kinase Kinases
  • Cisplatin